Thymus Cancer
8
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Integrated Cancer Repository for Cancer Research
Prospective Data Collection Initiative on Thoracic Malignancies
Molecular Analysis of Thoracic Malignancies
The Registry of Oncology Outcomes Associated with Testing and Treatment
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
B-Receptor Signaling in Cardiomyopathy